U.S. Markets closed

ArrowHead Research RNAi candidate reduces hepatitis B DNA in chimpanzee

Arrowhead Research announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus supports findings from rodent models indicating that it can knock down HBV DNA and key viral antigens. The chimpanzee being treated has had chronic HBV for over 30 years, has high viral-titer and antigenemia, and nearly 100% of hepatocytes stain positive for HBV. Studies are ongoing and additional data will be discussed at an analyst and investor event on March 25, and at upcoming scientific conferences.